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Abstract 
Mantle cell lymphoma (MCL) is a comparatively rare non-Hodgkin's lymphoma 
characterised by overexpression of cyclin D1. Many patients present with or progress to 
advanced stage disease within three years. MCL is considered an incurable disease with 
median survival between 3-4 years. We have investigated the role(s) of CCN1 (CYR61) and 
cell cycle regulators in progressive MCL.  
We have used the human MCL cell lines REC1<G519<JVM2 as a model for disease 
aggression. The magnitude of CCN1 expression in human MCL cells is REC1>G519>JVM2 
cells by RQ-PCR, depicting a decrease in CCN1 expression with disease progression. 
Investigation of CCN1 isoform expression by western blotting showed that whilst expression 
of full-length CCN1 was barely altered in the cell lines, expression of truncated forms (18-20 
and 28-30 kDa) decreased with disease progression.  
We have then demonstrated that cyclin D1 and cyclin dependent kinase inhibitors (p21CIP1and 
p27KIP1) are also involved in disease progression. Cyclin D1 was highly expressed in REC1 
cells (OD: 1.0), reduced to one fifth in G519 cells (OD: 0.2) and not detected by western 
blotting in JVM2 cells. p27KIP1 followed a similar profile of expression as cyclin D1. 
Conversely, p21CIP1 was absent in the REC1 cells and showed increasing expression in G519 
and JVM2 cells. Subcellular localization detected p21CIP1/ p27KIP1 primarily within the 
cytoplasm and absent from the nucleus, consistent with altered roles in treatment resistance.  
Dysregulation of the CCN1 truncated forms are associated with MCL progression. In 
conjunction with reduced expression of cyclin D1 and increased expression of p21, this 
molecular signature may depict aggressive disease and treatment resistance.  
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Abbreviations:  
MCL             Mantle cell lymphoma 
NHL             Non Hodgkin's Lymphoma 
CCND1        Cyclin D1 
CDK4 or 6   Cyclin-dependent kinase 4 (CDK4) or cyclin-dependent kinase 6 
pRb              Retinoblastoma protein 
ATM            Ataxia telangiectasia mutated 
CYR61         Cysteine-rich protein 61 
AML            Acute myeloid leukaemia 
SP                 Signal peptide  
IGFBP          Insulin like growth factor binding domain 
VWC            Von Willebrand type C repeat 
TSP-1           Thrombospondin type 1 domain 
CT                Cysteine rich carboxyl terminal 
HSPGs         Heparan sulfate proteoglycans 
BMP            Bone morphogenetic protein 
TGF-β          Transforming growth factor β 
VEGF          Vascular endothelial growth factor 
MMPs         Matrix metalloproteinases 
MM             Multiple myeloma 
OSC            Oesophageal squamous carcinoma 
MEK/ERK  Mitogen-activated protein kinase/extracellular-signal-regulated kinase 
OAFs          Osteoclast activating factors 
OBIs           Osteoblast inhibitors 
IL-6            Interleukin-6 
p21CIP1        (Cdk Interacting Protein 1) 
p27KIP1        (Kinase Inhibitory Protein 1) 
p57KIP2        (Kinase Inhibitory Protein 2) 
TNBC         Triple negative breast carcinoma 
FOXO3a     Forkhead box O3 
PCNA         Proliferating cell nuclear antigen 
OSCC         Oral squamous cell carcinoma 
HCC           Hepatocellular carcinoma 
NLS           Nuclear Localisation Signal 
DCIS          High-grade ductal carcinoma in situ 
NSCLC      Non-small-cell lung cancer  
  
Introduction 
Mantle cell lymphoma (MCL) is a distinct subset of B-cell Non Hodgkinʼs Lymphoma (NHL) 
characterised by overexpression of cyclin D1 as a result of t(11;14)(q13;q32) chromosomal 
translocation (Pérez-Galán, Dreyling & Wiestner, 2011). This translocation juxtaposes the 
cyclin D1 gene on chromosome 11q13 with the immunoglobulin heavy chain gene on 14q32 
which leads to cyclin D1 overexpression and the dysregulation of the cell cycle (O’Connor, 
2007; Zucca & Bertoni, 2013). The clinical course of this disease is highly variable and 
ranges from indolent classic morphology to aggressive variants with blastoid or pleomorphic 
morphology (Royo et al., 2012). MCL is characterised by almost inevitable relapses; many 
patients present with or progress to advanced stage disease within three years due to 
increasing resistance to chemotherapy and other agents (Dreyling et al., 2018; Liu, Zhang & 
Zhong, 2015). MCL is broadly considered an incurable disease with the median survival of 
patients being 3-4 years.  
The REC1, G519, JVM2 cell line model for MCL progression 
In this study, we have used three human MCL cell lines REC1, Granta 519 (G519) and JVM2 
as a model for MCL disease progression. The 2016 revision of World Health Organisation 
classification of lymphoid neoplasms describes the variants of MCL in addition to the 
characteristic Cyclin D1 rearrangent (i) 2 types of clinically indolent forms with either 
Immunoglobulin heavy chain variable region gene (IGHV) unmutated or minimally mutated 
and usually with expression of SOX11 typically involving lymph nodes or extranodal sites, 
(ii) acquisition of additional molecular or cytogenetic abnormalities leading to an aggressive 
blastoid or pleomorphic phenotype and (iii) leukaemic non-nodal MCL develops from IGHV 
mutated and SOX11 negative B cells with usual bone marrow and / or spleen involvement 
where abnormalities in TP53 contributes to enhance aggressive nature (Swerdlow et al., 
2016). REC1 cells display unmutated IGHV with expression of SOX11 (Beà et al., 2013) 
consistent with the classic indolent forms of MCL. GRANTA 519 (G 519) cells display 
blastoid phenotype with SOX11 positivity and amplification of BCL2 gene leading to Bcl2 
overexpression enhancing cell survival associated with the aggressive blastoid variant forms 
(Queirós et al., 2016; Rudolph et al., 2004). JVM2 cells are IGHV unmutated and SOX11 
negative, expressing low levels of cyclinD1 with increased expression of cyclin D2, BCL2 
positive (Tucker et al., 2006) and is considered a blastoid variant (Camps et al., 2006) 
consistent with the aggressive blastoid variant, SOX11 negativity overlaps with the 
aggressive leukaemic non-nodal MCL forms. In addition, the cell lines show increasing 
resistance to lenalidomide in the order of REC1<G519<JVM2 (Zhang et al., 2008) with 
G519 and JVM2 cells also showing increased resistance to Ibrutinib (Balsas et al., 2017). 
REC1 cells are observed as early stage/ indolent MCL showing sensitivity to conventional 
therapy in contrast to G519 and JVM2 cell lines which behave consistently with aggressive 
stages (Nordgren, Hegde & Joshi, 2012; Rauert‐Wunderlich et al., 2016). 
Cyclin D1 and cell cycle progression 
Overexpression of cyclin D1 (CCND1) as a result of t(11;14) chromosomal translocation is 
the hallmark feature of mantle cell lymphoma (Cassaday et al., 2015). Cyclin D1 plays a 
central role in the cell cycle regulation by binding to either cyclin-dependent kinase 4 (CDK4) 
or CDK6. The CCND1-CDK4 or CCND1-CDK6 complex phosphorylates the retinoblastoma 
protein (pRb) which leads to degradation of CCND1 suppressor effect on cell cycle 
progression. This process leads to release of the E2F family of transcription factors and then 
S-phase entry (Cassaday et al., 2015). E2F transcription factor regulates genes that encode 
DNA replication and cell cycle control (Nevins, 2001). In MCL, CCND1 overexpression 
leads to hyperphosphorylate pRb and accumulation of E2F which facilitates the G1/S 
transition and uncontrolled cell proliferation (Cassaday et al., 2015). CCND1 is upregulated 
in almost all MCL patients, however cyclin D1 alone is insufficient to promote MCL. 
Additional oncogenic aberrations have been implicated in the generation of MCL, including, 
c-Myc overexpression, lack of the ataxia telangiectasia mutated (ATM) gene or p53 
dysregulation (Müller et al., 2013). Many secondary genetic events are involved in MCL 
lymphomagenesis and include inactivation of the DNA damage response pathways, 
activation of cell-survival pathways, and suppression of apoptosis. Additional oncogenic 
aberrations are likely to contribute to the development of MCL involving cell proliferation, 
survival, and interactions with microenvironment (Jares, Colomer & Campo, 2012; Müller et 
al., 2013). Mutations within stem cell signalling pathways have been identified that may 
contribute to the pathogenesis of this disease. For example, Notch1 mutations are found in 12% 
of MCL and are associated with poor survival, suppression of the Notch pathway in MCL, 
decreased cell proliferation and increased apoptosis (Kridel et al., 2012). Similarly, 
deregulation of the Wnt canonical pathway was found in MCL by  inactivation of  phospho-
GSK3B suggesting that the Wnt pathway may also contribute to pathogenesis (Gelebart et al., 
2008). Further investigations are required to develop novel, effective therapeutic agents for 
MCL. 
Many studies have indicated that activation or upregulation of cell cycle regulators, p21, p27 
and cyclin D1 are induced through CCN1 signalling (Sawai et al., 2007; Tong et al., 2004; 
Xie et al., 2004), whilst the functional effect or output appears to be cell type specific. In 
2014, (Saglam et al.) have found that induction of cyclin D1 expression in grade ductal 
carcinoma in situ (DCIS) can occur through CCN1 signalling leading to cell cycle 
progression. CCN1 protein promoted cell cycle arrest by increased cell senescence at G0/G1 
phase through activation notch-1-p21 pathway and reduced proliferation of human 
trophoblast cells (Kipkeew et al., 2016). Similarly, CCN1 signalling induced accumulation of 
p53 and p21 driving cell senescence leading to suppression of lung cancer cell proliferation 
(Jim Leu et al., 2013).  
CCN1 (CYR61)  
CCN1, a matricellular protein is involved in stem cell signalling within the haematopoietic 
microenvironment (McCallum & Irvine, 2009; Wells et al., 2015) and has been associated 
with a number of haematological malignancies including acute myeloid leukaemia (AML) 
and multiple myeloma (MM) (Crawford & Irvine, 2016). CCN1, also known as CYR61, 
belongs to CCN family of proteins that are comprised of a signal peptide (SP), Insulin like 
growth factor binding domain (IGFBP), Von Willebrand type C repeat (VWC), a hinge 
region leading to the Thrombospondin type I domain (TSP-1) and cysteine rich carboxyl 
terminal (CT) (Planque & Perbal, 2003).  
CCN1 has been shown to be involved in a diverse array of cellular processes including 
regulation of cell migration, cell adhesion, proliferation, differentiation, apoptosis and 
angiogenesis through direct binding to cell surface receptors such as integrins and heparan 
sulfate proteoglycans (HSPGs) (Jandova et al., 2012; Kireeva et al., 1996). CCN1 is a ligand 
for integrins and acts through direct binding to integrins (via VWC, TSP-1 and CT domains) 
and HSPGs in order to enhance specific functions (Leu et al., 2004). Increasing evidence has 
shown that CCN1 promotes cell adhesion by binding to integrin α6β1-HSPG co-receptors in 
fibroblasts (Todorovicç et al., 2005), αMβ2 in murine macrophages (Bai, Chen & Lau, 2010) 
αDβ2 in macrophage foam cells (Yakubenko, Yadav & Ugarova, 2006), α‖bβ3 in activated 
platelets (Jedsadayanmata et al., 1999). CCN1 may interact with other growth factors such as 
bone morphogenetic proteins (BMP), transforming growth factor β (TGF-β) and vascular 
endothelial growth factor (VEGF) which need more investigation (Lau, 2011).  Recently, it 
has seen that ALK5 suppression prevents TGF-β-induced CCN1 expression in human dermal 
fibroblasts (Thompson, Murphy-Marshman & Leask, 2014). More importantly, CCN1 is a 
transcriptional target of TGF-β and may potentiate an autocrine regulatory mechanism in 
tumourigenesis (Bartholin et al., 2007) and is similarly a target of the Wnt B catenin pathway 
as demonstrated in mesenchymal stem cell differentiation to osteoblasts and hepatocellular 
carcinoma (Si et al., 2006; Li et al., 2012). Constitutive activation of the Wnt Signalling 
pathway was also identified in MCL (Gelebart et al,. 2008), with MCL initiating cells (MCL-
ICs) displaying activation of the Wnt signalling pathway (Samaniego et al., 2014). Targeting 
of Wnt signalling specifically reduces the growth of MCL-ICs (Mathur et al., 2015).           
CCN1 can be observed in cancer as “a double-edged sword” (Lau, 2011) where altered 
CCN1 expression in various cancers may induce or suppress tumour growth (Feng, Wang & 
Ren, 2008; Holloway et al., 2005). CCN1 plays unique roles in different cancers: it is a 
tumour promoter in cancers of the breast (Menendez et al., 2005), prostate (Sun et al., 2008), 
pancreatic (Maity et al., 2014), gastric carcinogenesis (Cheng et al., 2014), ovarian 
carcinoma (Gery et al., 2005), colorectal (Jeong et al., 2014), myeloma (Roodman, 2014) and 
acute myeloid leukaemia (AML) (Niu et al., 2014) due to either overexpression of CCN1 or 
truncated isoforms. Paradoxically, CCN1 is a tumour suppressor in melanoma (Dobroff et al., 
2009), non-small cell lung cancer (Tong et al., 2001) and endometrial adenocarcinoma 
(Chien et al., 2004). Full-length CCN proteins can play an anti-proliferative role, while 
truncated isoforms may induce tumour proliferation (Planque & Perbal, 2003). For example, 
when CCN1 is cleaved by plasmin, this releases a truncated isoform of CCN1 (28kDa) 
supporting endothelial cell migration in breast carcinoma cells (Pendurthi et al., 2005). In 
2013, (Choi et al., 2013) identified truncated CCN1 in the vitreous fluid secretome of 
proliferative diabetic retinopathy patients rather than full-length protein. Furthermore, a 
truncated isoform of CCN1 which includes complete or partial length forms of the two-
modules form IGFBP-VWC is generated by proteolytic cleavage of matrix metalloproteinase 
MMPs (Choi et al., 2013). In addition to proteolysis generating production of a CCN1 
truncated isoform, it may also be generated by alternative mRNA splicing (Perbal, 2009).  
Increasing evidence suggests that CCN1 plays important roles in tumour development, 
including migration, survival, proliferation and metastasis (Sun et al., 2008). In AML, CCN1 
induces tumour survival through activation of the Ras/Raf/MEK/ERK pathway by up 
regulating c-Myc and Bcl-xL and by down regulating Bax (Niu et al., 2014). Similarly, 
CCN1 confers human breast cancer resistance to chemotherapeutic agent-induced apoptosis 
and suppresses apoptosis by activating the integrins/NF-kb/XIAP signalling pathway (Lin et 
al., 2004). CCN1 has been found in sites of bone remodelling, involvement enhancing 
osteoblast differentiation while suppressing osteoclast formation (Si et al., 2006).  
Furthermore, CCN1 has been implicated in Wnt3A-induced osteoblast differentiation of 
mesenchymal stem cells (Si et al., 2006). In vivo, (Johnson et al., 2014) have reported that 
overexpression of CCN1 which produced by mesenchymal cells in bone marrow 
microenvironment of patients with monoclonal gammopathy of undetermined significance 
(MGUS), asymptomatic myeloma (AMM), and multiple myeloma (MM) suppressed tumour 
cell growth and reduced MGUS progression to MM. However, CCN1 may enhance myeloma 
cell viability through supporting survival of the INA-6 myeloma cell line lacking interleukin-
6(IL-6) (Dotterweich et al., 2014).  
Many studies have indicated that activation or upregulation of cell cycle regulators, p21, p27 
and cyclin D1 induce through CCN1 signalling (Sawai et al., 2007; Tong et al., 2004; Xie et 
al., 2004). In 2014, (Saglam et al.) have found that induction of cyclin D1 expression in 
grade ductal carcinoma in situ (DCIS) can occur through CCN1 signalling leading to cell 
cycle progression. However, CCN1 protein promoted cell cycle arrest by increased 
senescence-cell at G0/G1 phase through activation notch-1-p21 pathway and reduced cell 
proliferation of human trophoblast cells (Kipkeew et al., 2016). Moreover, CCN1 signalling 
induced accumulation of p53 and p21 driving senescence of cell leading to suppress lung 
cancer cell proliferation (Jim Leu et al., 2013). 
p21 
p21CIP1 (p21) belongs to the CIP/KIP family of proteins that regulate cell cycle progression.  
The CIP/KIP family comprises three members; p21CIP1 (Cdk Interacting Protein 1), p27KIP1 
(Kinase Inhibitory Protein 1) and p57KIP2 (Kinase Inhibitory Protein 2) (Bretones, Delgado & 
León, 2015) which bind and inhibit most cyclin-CDK complexes. The CIP/KIP family of 
proteins, particularly p21, plays an essential role in cell cycle control, halting the transition 
from G1 phase to S phase (Pérez-Sayáns et al., 2013). Two pathways regulate p21; a p53-
dependent pathway (in response to DNA damage which activates p53 leading to upregulation 
of p21 and repression of cell growth in G1 phase with potential DNA repair or stimulation of 
programmed cell death) and a p53-independent pathway, in which cellular growth factors 
regulate p21 expression (Brennan et al., 2002; Ciccarelli et al., 2005). p21 binds to CCND1-
CDK4 or -CDK6 complex and inhibits the kinase activity of CDKs in response to many 
stimuli leading to regulation G1/S progression, at the restriction point. This process leads to 
repression of phosphorylation of pRb protein which in turn prevents the expression of E2F 
factors and blocks G1/S transition (Zhang & Yan, 2012).  
In addition to negative regulation of the cell cycle, p21 can regulate gene transcription;  p21 
suppresses E2F transcription factor through a pathway independent of CDKs or Rb (Perkins, 
2002). p21 is involved in controlling cellular growth by suppressing of E2F1 transcription 
factor via  Wnt4 expression and Notch 1 activation (Devgan et al., 2005) and p21 stimulates 
NFkb-mediated transcription by activation of p300 and CBP (Perkins, 2002). Studies have 
identified additional roles for p21, in cancer it is a tumour suppressor through cell cycle arrest 
and blocking DNA synthesis by binding to proliferating cell nuclear antigen (PCNA) (Waga 
et al., 1994) or as oncogenic factor, promoting carcinogenesis and tumour development 
(Roninson, 2002). The expression of p21 varies in different cancers, it is down regulated in 
small-cell lung (Komiya et al., 1997), colorectal (Zirbes et al., 2000), cervical (Lu et al., 
1998a), and head and neck cancer (Kapranos et al., 2000) that are associated with tumour 
progression. In contrast, it is upregulated in prostate (Baretton et al., 1999), ovarian 
(Ferrandina et al., 2000), breast, oesophageal squamous cell carcinomas, and in brain 
tumours (Roninson, 2002). The function of p21 depends on subcellular localization which 
may be nuclear, cytoplasmic or mitochondrial. p21 regulates cell proliferation and 
differentiation by localizing in the nucleus (Abbas & Dutta, 2009), whilst p21 enables 
resistance to DNA damage by inhibiting proteins essential for apoptosis by localising to the 
cytoplasm or mitochondria, enhancing tumourigenesis (de Renty, DePamphilis & Ullah, 2014; 
Sohn et al., 2006) 
p27 
In G1 phase of cell cycle, reviewed in (Hirama & Koeffler, 1995) p27 binds to CCNE-CDK2 
complex and inhibits the catalytic activity of CDK2 resulting in cell cycle arrest at the 
restriction point in response to DNA damage or anti-mitogenic signals. As a result, this 
prevents the phosphorylation of pRb which leads to block in the transcription of genes 
required for G1/S progression (Toyoshima & Hunter, 1994). Beyond the restriction point, cell 
cycle proceeds independent of mitogenic signals (Coats et al., 1996). 
 Interestingly, p27KIP1 and p21CIP1 have an important role in promotion of assembly of 
CCND-CDK4/6 complexes (LaBaer et al., 1997). This interaction leads to sequestration of 
p27 in CCND-CDK4 complex which blocks inhibition of the CCNE-CDK2 complex (Perez‐
Roger et al., 1999). Binding of p27KIP1 with CCND-CDK4 complex suppresses the kinase 
activity of CDK4 (Ray et al., 2009). Expression of p27KIP1 is reduced in several types of 
cancer associated with poor prognosis including breast (He et al., 2012), prostate (Roy et al., 
2008), lung and colon cancer (Timmerbeul et al., 2006). In contrast, p27KIP1 is overexpressed 
in hepatocellular carcinoma (HCC) which is associated with longer disease free survival (Qin 
& Ng, 2001). In MCL, Quintanilla-Martinez et al. (2003) suggested overexpression of cyclin 
D1 contributed to a change in p27KIP1 levels leading to inhibition of cellular growth.  
In addition to cell cycle regulation, there is some evidence that p27KIP1 has important roles in 
apoptosis, transcriptional activation, and migration depending on its localization. In the 
nucleus, it has an essential role to inhibit cell growth and is considered as a tumour 
suppressor (Jeannot et al., 2015). Phosphorylation of specific sites on p27KIP1 leads to its 
export into the cytoplasm where it can act as a tumour promotor as reviewed in (Besson, 
Dowdy & Roberts, 2008). Many studies have shown that cytoplasmic p27KIP1 in cancer 
including melanoma (Chen et al., 2011; Denicourt et al., 2007), ovarian carcinoma (Duncan 
et al., 2010), renal cell carcinoma (Kruck et al., 2012), osteosarcoma (Li et al., 2016) and 
acute myelogenous leukaemia (Min et al., 2004) is associated with cell migration, high 
tumour grade and metastasis, poor prognosis and survival. Moreover, cytoplasmic p27KIP1 
contributed to treatment resistance mediated suppression of apoptosis in Her2+ breast cancer 
cells (Zhao et al., 2014).            
This study investigated the expression of CCN1 and cell cycle regulators Cyclin D1, p21 and 
p27 in progressive MCL.   
  
Materials and Methods  
Cell culture 
Human Mantle Cell Lymphoma cell lines REC1, G519 and JVM2 were purchased from the 
Deutsche Sammlung von Mikroorganismen and Zellkulturen (DSMZ-Germany). All cell 
lines were cultured in Roswell Park Memorial Institute (RPMI) 1640 (Gibco) supplemented 
with 10% FBS (Gibco) and were incubated at 37° C in a humidified atmosphere of 5% CO2.  
Cells were passaged twice weekly to maintain log phase. Experiments were conducted within 
10 passages from cell recovery and cells were seeded at 2x105 cells per ml for experimental 
procedures. Cells were counted using a haemocytometer and viability assessed using the 
trypan blue exclusion assay.  
Normal peripheral blood (nPB) samples were obtained from Normal blood donors (n=5) via 
NHS Blood and Transplant Bristol (NHSBT, Bristol, UK) with material transfer agreement 
and approval for use via Plymouth University ethics committee. Lymphocytes were extracted 
using Lymphoprep™ (Axis Shield, UK) using manufacturer’s instructions and cells 
harvested in Trizol® reagent (Fisher Scientific, UK) for RNA analyses.  
Protein extraction and quantification 
Total cell lysates for three cell lines (REC1, G519 and JVM2) were prepared in 
Radioimmune Precipitation Assay buffer (RIPA): Tris 50 mM, NaCl 150 mM, Triton X-100 
1%, Na-Deoxycholate 0.5%, SDS 0.1% supplemented with Complete™ protease inhibitor 
(Roche UK) and stored at -20 °C until required.  
Subcellular Fractions 
Nuclear, mitochondria and cytoplasmic proteins from REC1, G519 and JVM2 cell lines were 
extracted using the Cell Fraction Kit-Standard (Abcam, UK) according to manufacturer 
instructions with the following modifications: reduced cell number to 1x106/ml incubated 
with 500 µl of buffer A (1X) and samples were incubated for 8 minutes to extract clean 
mitochondrial fractions. Buffer A (1X) was prepared using 5 ml 2X buffer A stock, 4900 µl 
dH2O and 100µl PI 100X (Halt Protease Inhibitor Single-Use Cocktail EDTA-Free, 
ThermoScientific). All fractions were stored at -80 °C until required.  
Protein was quantified using the micro BCA™ Assay Kit following the supplier instructions 
(Pierce, ThermoScientific, UK). The subcellular fractions for nuclear, cytoplasmic and 
mitochondrial extracts were run simultaneously on one gel (NuPage 10 well 10% Bis Tris gel 
(Invitrogen, UK)) to enable direct comparison. Experiments were conducted in triplicate 
(n=3).  
Western blotting  
Protein samples (10 µg) were loaded on a 10% NuPAGE® Bis-Tris Gels (Invitrogen UK) 
and transferred onto a PVDF membrane (Millipore, UK). Membranes were blocked with 2.5% 
skimmed milk for 30 minutes. Membranes were then incubated overnight at 4 °C with 
primary antibody (rabbit anti-p21CIP1 (2947S) (1:1000, Cell Signalling Technology), rabbit 
anti-p27KIP1 (3688s) (1:1000, New England Biolabs), mouse cyclin D1 (1:1000, Cell 
Signalling Technology), rabbit anti-CCN1 (ab24448, Lot # GR26258-7) (1:2000, Abcam), 
anti-GAPDH (ab9485) (1:2500, Abcam), mouse anti-COX IV (ab33985) (1:1000, Abcam), 
rabbit anti Histone H3 (9717s)(1:1000, New England Biolabs)). Membrane was washed with 
PBS-T and incubated with an appropriate secondary antibody conjugated to HRP. Bands 
were detected using chemiluminesence (Thermo Scientific SuperSignal®West Dura 
Extended Duration Substrate) and viewed using the Image Quant LAS4000. 
RNA extraction and cDNA synthesis 
Total RNA was extracted using Trizol® reagent (Fisher Scientific, UK). Trizol (1ml for 
1x106 cells) was pipetted up and down several times until the samples were homogenised. 
200 µl of chloroform was added per ml of Trizol®, shaken vigorously for 15 seconds and 
incubated at room temperature for 2-3 minutes. Samples were centrifuged at 13000 rpm for 
15 minutes at 4 °C. The upper layer was decanted to new tubes and 500 µl isopropanol added 
and incubated at room temperature for 10 minutes. Samples were centrifuged at 13000 rpm 
for 15 minutes at 4 °C. Supernatant was discarded and the white RNA pellet washed three 
times with 70% ethanol. RNase free water was used to re-suspend the pellet. Samples were 
stored at -80 °C until required. RNA quantity and purity was measured using a nanodrop 
spectrophotometer using A260/A280 ratios (Thermo-Fisher scientific, Waltham, MA, USA). 
cDNA was synthesised using 2 µg of total RNA in 20 µl volume using the High Capacity 
RNA to cDNA kit (Applied Biosystems) according to the manufacturer’s instructions. cDNA 
samples were stored at -20 °C until required. Negative template controls consisting of 
reaction without cDNA were run for all experiments.  
RQ-PCR 
The quantitative real-time PCR was performed by using StepOne Software v2.3 analytical 
software (Thermo-cycler 96 well plate Real time PCR, Applied Biosystems, US) in a volume 
of 12.5 µl containing 1µl cDNA (100ng), 0.625 µl ppp, 6.25 µl 2xMM (Prime time Master 
Mix, Integrated DNA technologies). The PCR reaction conditions were 95 °C for 3 minutes, 
followed by 40 cycles comprising denaturation at 95 °C for 5 seconds, annealing at 60 °C for 
30 seconds. Predesigned assay reagents with FAM/ TAMRA fluorescence were used for 
CCN1 (Hs00155479_m1), GAPDH ((PT.39a.22214836) from Integrated DNA Technologies), 
p21 (00355782-M1), p27 (01597588-M1) and cyclin D1 ((00765553-M1) from Applied 
Biosystems). GAPDH used as an endogenous control, gene expression levels were reported 
using the ∆∆CT method with experimental samples run in triplicate and independent 
replicates of RNA completed in triplicate for reporting.  
Statistics 
Statistical analysis was performed on data from at least 3 independent experiments. For RQ-
PCR, samples were run in triplicate and then independent replicates performed in triplicate 
for publication. Students t-test was performed to identify significance between samples and 
where p<0.05 was deemed significant.  
 
  
Results 
CCN1 expression is inversely correlated with MCL aggressiveness    
In order to assess the potential role(s) of CCN1 in MCL, we have investigated CCN1 
expression using RQ-PCR and Western blotting.  REC1, G519, JVM2 human MCL cell lines 
were used as a model for MCL disease progression in the order from indolent to aggressive 
disease REC1<G519<JVM2 respectively.   
RQ-PCR for CCN1 expression shows an inverse relationship with disease aggression. 
Normal peripheral blood (nPB) lymphocytes from donors were also assessed for CCN1 
expression. CCN1 was barely detected in nPB (CT=34.9 ± 0.75) and therefore set to a fold 
change of 1 to asses relative expression within the MCL cell lines. CCN1 expression was 
high in REC1 cells (Fold change 67.18 ± 0.14) and sequentially decreased in progressive 
G519 cells (Fold change 20.1 ± 0.22) and JVM2 cells (Fold change 2.86 ± 0.52) (Figure 1A).   
Investigation of CCN1 total protein expression using western blot analysis showed CCN1 
protein expression at the following approximate molecular weights; 42kDa consistent with 
expression of full length CCN1, 28-30kDa and 18-20kDa consistent with expression of 
truncated proteins. Expression of full–length CCN1 barely altered through the cell lines 
however, expression of the truncated form (18-20kDa) was high in REC1 cells (OD:1.0) 
reduced in G519 cells (OD:0.5) and barely detected in JVM2 cells (Figure 1B and Fig 1C). 
Reports from a previous study (Choi et al., 2013) suggests the 28-30kDa moiety could 
comprise the SP, IGFBP, VWC and TSP-1 domains whilst the 18-20 kDa moiety could be 
either the SP, IGFBP, VWC fragment or TSP-1 and CT fragment, or potentially a mix of both 
(Figure 1D).  
Cyclin D1 is downregulated in progressive MCL  
We have investigated cyclin D1 expression using RQ-PCR and Western blotting using total 
protein extracts from the three MCL cell lines; REC1, G519 and JVM2. RQ-PCR shows 
cyclin D1 expression is high in REC1 cells and decreased in G519 and JVM2 cells consistent 
with deregulation of cyclin D1 in aggressive disease (Figure 2A).  Fold changes in cyclin D1 
expression were 10.1, 4.6 and 1.0 for REC1, G519 and JVM2 respectively.        
Cyclin D1 total protein expression mirrored that of the gene expression where cyclin D1 was 
highly expressed in the Rec1 cells (OD: 1.0), reduced to one fifth in the G519 cells (OD: 0.2) 
and not detected by western blotting in the JVM2 cell line (Figure 2B and 2C).  
High expression of p21CIP1 and down expression of p27KIP1 in aggressive 
MCL   
Cyclin dependent kinase inhibitors, p21CIP1 and p27KIP1, were also investigated for an 
involvement in disease progression.  
RQ-PCR shows increasing expression of p21 with disease progression whilst expression 
levels of p27 are decreased with disease progression in G519 and JVM2 cells (Figure 2D).  
Total cell lysates showed that p21CIP1 was not detected in REC1 cells but had increasing 
expression in G519 (OD: 0.6) and JVM2 cells (OD: 1.0) (Figure 2E and F). Whilst RQ-PCR 
and western blotting show that p27KIP1 expression was high in the REC1 and decreased with 
disease progression in G519 and JVM2 cells (Figures 2G-I). Total cell lysates showed that 
p27KIP1 was high expressed in REC1 (OD: 1.5) and decreased in G519 (OD: 1.0) and not 
detected in JVM2 cells (Figures 2H and 2I).      
Altered subcellular localization of p21CIP1 and p27KIP1 portray resistance in 
progressive MCL  
To investigate the subcellular localization of p21CIP1 and p27KIP1 in MCL, we extracted 
cytoplasmic, mitochondrial and nuclear protein from cells and performed western blotting.  
Expression of p21CIP1 was not detected in any fraction for early stage REC1 cells. For the 
progressive G519 and JVM2 cells, p21CIP1 was primarily expressed in the cytoplasm and was 
not detected in the nucleus (Figure 3A). Expression of p21CIP1 was detected in the 
mitochondrial fraction for JVM2 cells. Blotting for GAPDH (cytoplasmic), COX IV 
(Mitochondrial) and Histone 3 (Nuclear) markers were used as controls for each fraction.  
For p27KIP1, expression was only detected in the cytoplasmic fraction and not in 
mitochondrial or nuclear fractions (figure 3B). GAPDH (cytoplasmic), COX IV 
(Mitochondrial) and Histone 3 (Nuclear) markers were used as loading controls and to ensure 
clean fractions were obtained for each, without cross contamination during the fractionation 
process.  
 
  
Discussion 
MCL is considered an aggressive disease and has one of the worst outcomes among B-cell 
lymphomas due to the dysregulation of the DNA damage response pathways accompanied 
with abnormal cell survival mechanisms suppressing apoptosis (Campo & Rule, 2015; Moros 
et al., 2014). MCL characterised by overexpression of cyclin D1 as a result of t(11;14) 
chromosomal translocation that leads to dysregulation of the cell cycle (O’Connor, 2007; 
Zucca & Bertoni, 2013). Furthermore, MCL is characterised by clinical course where variants 
are subdivided into indolent form (classic morphology) and aggressive (blastoid or 
pleomorphic appearance) (Kridel et al., 2012). The heterogeneous biology and aggressive 
behaviour of MCL present a challenge for designing standard therapies (Smith, 2011) and 
therefore require further investigation to identify more effective treatment strategies.  
In this study, we have investigated the role(s) of CCN1 in MCL and investigated cell cycle 
regulation using expression of cyclin D1, p21CIP1 and p27KIP1 in the cell line model 
representing disease progression in MCL where the magnitude of aggressive behaviour is in 
the order REC1<G519<JVM2. CCN1 dysregulation was identified in MCL progression 
where CCN1 was highly expressed in the REC1 cells and reduced in the aggressive G519 and 
JVM2 cells. CCN1 expression decreases with disease progression. We found that the lower 
expression of CCN1 in aggressive MCL cell lines (G519 and JVM2) is additional risk factor 
for disease progression. However, many studies have indicated that the high expression of 
CCN1 is implicated in disease progression, tumorigenesis and invasion of hepatocellular 
carcinoma (HCC) (Li et al., 2012), breast cancer (O'Kelly et al., 2008), prostatic carcinoma 
(D'Antonio et al., 2010), gliomas (Xie et al., 2004b) and gastric cancer (Lin et al., 2007). 
Further investigation demonstrated that whilst full-length CCN1 remains relatively constant 
within the cell lines, the 18-20 kDa truncated form is decreased within aggressive G519 and 
JVM2 cells. Previous reports identify that this truncated form could potentially be a fragment 
consisting of the SP-IGFBP-VWC domains or the TSP-1-CT domains (Choi et al., 2013) 
inferring that either transcriptional control or post-translational control of CCN1 (via 
degradation by MMP2 / MMP14 for example (Choi et al., 2013)) is lost within aggressive 
MCL. In 2006, Planque et al., have found that full length of CCN3 inhibited cell growth 
whilst a truncated isoform induced “morphological transformation of chicken embryo 
fibroblasts” suggesting a role in oncogenic activity. The truncated isoform of CCN3 
translocated to the nucleus of cancer cell lines supporting the role of the carboxyl terminal 
being involved in transcriptional regulation. Increasing evidence indicates the Nuclear 
Localisation Signal (NLS), a short peptide motif mediating nuclear localisation of proteins, is 
located in the CT module of CCN3 (lysine-rich PTDKKGKKCLRTKKSLKA) (Planque, 
2006). Perbal (1999) found nuclear localisation of the truncated isoform of CCN3 (NOV) 
protein (31/32kDa) in the nucleus of 143 and HeLa cells. It is suggested the truncated isoform 
may be deficient of N-terminus to have a role in the gene expression of target cells since 
antibodies against the C-terminus of CCN3 / NOV were used (KKGKKCLRTKKS). CCN1 
(CYR61) and CCN3 (NOV) are members in the CCN family of matricellular proteins sharing 
40%-60% amino acid homology which may infer potential for the CCN1 truncated isoform to 
have nuclear localisation and role(s) in gene regulation (Perbal, 1999; Planque & Perbal, 
2003). Supporting this, the CCN3 NLS region (PTDKKGKKCLRTKKSLKA)(Planque, 
2006) is highly conserved in the CCN1 CT domain (KKGKKCSKTKKS). This may suggest 
that the CCN1 truncated form (18-20 k Da) may translocate to the nucleus of MCL cell lines. 
This is consistent with CCN1 found in the nucleus of bladder smooth muscle cells (Chen & 
Du, 2007; Tamura et al., 2001).  
Full length CCN proteins can play an anti-proliferative role, whilst truncated isoforms may 
induce tumour proliferation (Planque & Perbal, 2003). The truncated isoform appears to have 
altered biological function(s) owing to CCN1 partition into the soluble phase (28kDa), 
diffusing freely within tissue and may act as an antagonist towards the full-length CCN1 form 
within the insoluble matrix (42kDa) (Pendurthi et al., 2005). For example, CCN1 is cleaved 
by plasmin and releases a truncated form of CCN1 (28kDa) which may support endothelial 
cell migration in breast carcinoma (Pendurthi et al., 2005). In 2013, (Choi et al.), found the 
CCN1 truncated form (11-23kDa) expressed in diabetic retinopathy patients instead of the 
full-length 42kDa protein. It is also postulated that a truncated isoform of CCN1 can arise due 
to alternative mRNA splicing (Perbal, 2009).  
In this study, Cyclin D1 was also deregulated in MCL and our findings are consistent with 
previous reports of cyclin D1 down regulation and disease progression (Peng, Chou & Hsu, 
1998). Interestingly, Saglam et al. (2014) have demonstrated that the up regulation of cyclin 
D1 and p53 are activated by the CCN1 pathway in high-grade ductal carcinoma in situ 
(DCIS). Consistent with these findings, we showed a positive association between CCN1 and 
cyclin D1 expression in all MCL cell lines. In other solid tumours, where cyclin D1 is 
overexpressed; breast, liver, lung, and brain cancer (Gillett et al., 1996; Hall & Peters, 1996; 
Molenaar et al., 2008) requires consistent signalling from the extracellular matrix and growth 
factors (Assoian & Klein, 2008).  
MCL progression involving down regulation of cyclin D1 and the up regulation of p21CIP1 
may contribute to treatment resistance (Abukhdeir & Park, 2008). We have shown that 
p21CIP1 levels increase with disease progression.  This is consistent with other studies that 
report overexpression of p21CIP1 was correlated with tumour progression; in breast 
(Ceccarelli et al., 2001) and ovarian carcinoma (Ferrandina et al., 2000) and in brain tumours 
(Jung et al., 1995). 
We have shown that p27KIP1 levels decrease with disease progression also consistent with 
findings from Izban et al. (2000), where p27KIP1 was overexpressed in early stage disease 
(typical MCL) and down regulated in aggressive stage (blastoid variants) where it was 
associated with a high proliferation rate of blastoid MCL. Conversely, in 1998 (Quintanilla-
Martinez et al.) showed expression of p27KIP1 was inversely associated with the proliferation 
rate of MCL cells; undetected in typical MCL cells (classic disease) associated with low 
proliferation rate but was overexpressed in the blastic variant of MCL cells (aggressive 
disease) with higher proliferation rate. 
P27KIP1 and p21CIP1 have important roles in promotion of assembly of CCND-CDK4/6 
complexes (LaBaer et al., 1997). This interaction leads to sequestration of p27KIP1 in CCND-
CDK4 complex which blocks inhibition of the CCNE-CDK2 complex (Perez‐Roger et al., 
1999). Furthermore, investigation of p21CIP1 expression in MCL progression showed down 
regulation at early stage disease and overexpression at advanced stage that mirrors its roles in 
MCL progression.  
More importantly, in cancer, the tumour suppressor function of p21CIP1 and p27KIP1 depends 
on their nuclear localization (Jeannot et al., 2015; Romanov, Pospelov & Pospelova, 2012). 
Many studies have found that phosphorylation of specific sites of p27KIP1 and p21CIP1 lead to 
their export into the cytoplasm where they can act as a tumour promotors and induce drug 
resistance (Ohkoshi, Yano & Matsuda, 2015; Zhao et al., 2014). In this study, p21CIP1 and 
p27KIP1 were found in the cytoplasmic fractions and absent in nuclear fractions of all three 
cell lines (REC1, G519 and JVM2). This suggests in MCL, p21CIP1 and p27KIP1 have lost 
their tumour suppressor roles and acquired tumour promoter roles by localisation to the 
cytoplasm.  Whilst mutation of p21CIP1 has not been investigated here, mutation of the p21CIP1 
gene frequently occurs in cancer cells leading to inactivation of p21CIP1 with loss of function 
to block the cell cycle, even when overexpressed (Lu et al., 1998b; Lukas et al., 1997). While 
regulation of p27KIP1 is different from other cell cycle inhibitors, p27KIP1 gene mutation is 
rare (Garrett-Engele et al., 2007).  
CCN1 likely plays key role(s) in haematopoiesis and in B cell development through 
modulation of stem cell signalling pathways, TGF β, BMP, Notch, Wnt-β catenin (McCallum 
& Irvine, 2009; Wells et al., 2015). CCN1 roles within haematological malignancy show 
CCN1 promotes survival and inhibits apoptosis in AML (Niu et al., 2014) and 
overexpression of CCN1 in multiple myeloma (MM) postponed tumour growth and 
suppressed bone destruction (Johnson et al., 2014). CCN1 signalling involves many stem cell 
pathways active within the bone marrow microenvironment where haematopoiesis ensues; 
CCN1 can activate the Wnt-β catenin-TCF4 signalling pathway in glioma cell (Xie et al., 
2004a) and induces Wnt3A osteoblast differentiation of mesenchymal stem cells (Si et al., 
2006). CCN1 in some cancers plays important roles in enhancing apoptosis, suppressing 
tumour growth, such as non-small-cell lung cancer (NSCLC) cell lines through activating the 
β-catenin-c-myc-p53-p21 signalling pathway  (Tong et al., 2004). Moreover, CCN1 enhances 
pancreatic cancer cell motility in vitro and cell tumorgenic growth in vivo by regulating 
sonic-Hedgehog through integrin-Notch-signalling pathway (Haque et al., 2012).  
In conclusion, CCN1 expression appears to be regulated in MCL, where reduced expression 
of the truncated forms (18-20 and 28-30 kDa) is associated with aggressive disease. In 
combination with reduced expression of cyclin D1 and increased expression of p21, this 
molecular signature may depict aggressive disease and treatment resistance. Further 
investigation will ascertain CCN1 role(s) in MCL progression.         
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Legends 
Figure 1 CCN1 expression in MCL progression. (A) RQ-PCR screen of MCL cell lines for 
CCN1 expression in normal peripheral blood (nPB), low-aggression phenotype (REC1) and 
in aggressive disease (G519 and JVM2). (B) Western blot showing CCN1 expression for the 
MCL cell lines, REC1, G519 and JVM2 (C) Optical densitometry for CCN1 band pattern by 
Western Blotting. (D) CCN1 domain structure of full length and potential truncated CCN1 
proteins adapted from Choi et al., 2013. GAPDH was used as a loading control, data 
generated were normalised against GAPDH control (n=3 independent samples) and (nPB, 
n=5 independent samples).     
 
Figure 2 Cyclin D1, p21 and p27 expression in MCL progression. RQ-PCR of cyclin 
D1 (A), p21 (D) and p27 (G) in MCL for REC1, G519 and JVM2 cells. Western blotting for 
expression of total protein for cyclin D1 (B), p21 (E) and p27 (H) in MCL for REC1, G519 
and JVM2 cells. Optical densitometry for western blotting of cyclin D1 (C), p21 (F) and 
p27 (I). Densitometry was performed on banding and data generated normalised against 
GAPDH loading control (n=3 independent replicates). 
 
Figure 3 Subcellular localisation of p21 and p27 in MCL. A Western blot for p21 cellular 
content for cytoplasmic, mitochondrial and nuclear fractions for REC1, G519 and JVM2 
cells.  B Western blot for p27 cellular content for cytoplasmic, mitochondrial and nuclear 
fractions for REC1, G519 and JVM2 cells. GAPDH, Histone 3 and COXIV were used as a 
loading control and to ensure clean fractions free from cross contamination during the 
fractionation process were obtained (n=3 independent samples). 
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